Bigfoot Biomedical Secures $57M In New Funding To Support Commercialization Of Diabetes Management System
As Bigfoot awaits FDA clearance for its Bigfoot Unity System, the diabetes treatment company’s business model calls for packing the System as part of a one-stop-shop monthly subscription model.
You may also be interested in...
Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.